Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
Overview
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
Associated Conditions
- Chronic Myelogenous Leukemia (CML)
- Essential Thrombocythemia (ET)
- Head and Neck Primary Squamous Cell Carcinoma
- Hypereosinophilic Syndrome (HES)
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
- Meningiomas
- Polycythemia Vera (PV)
- Sickle Cell Crisis
- Vaso-occlusive Crisis
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath